175 related articles for article (PubMed ID: 20010481)
1. Treatment of chronic hepatitis C.
Bihl F; Negro F
Minerva Med; 2009 Dec; 100(6):459-65. PubMed ID: 20010481
[TBL] [Abstract][Full Text] [Related]
2. [Attempts to treat chronic hepatitis C with HCV protease inhibitor].
Pawłowska M
Przegl Epidemiol; 2011; 65(1):35-8. PubMed ID: 21735833
[TBL] [Abstract][Full Text] [Related]
3. Dynamic evolution of therapy for chronic hepatitis C: how will novel agents be incorporated into the standard of care?
Zeuzem S; Nelson DR; Marcellin P
Antivir Ther; 2008; 13(6):747-60. PubMed ID: 18839776
[TBL] [Abstract][Full Text] [Related]
4. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
Ferraro D; Bonura C; Giglio M; Di Stefano R; Almasio PL; Di Marco V; Craxì A; Cacciola I; Squadrito G; Raimondo G
J Biol Regul Homeost Agents; 2003; 17(2):172-5. PubMed ID: 14518718
[TBL] [Abstract][Full Text] [Related]
5. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
Iacob S; Gheorghe L; Hrehoret D; Becheanu G; Herlea V; Popescu I
J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137
[TBL] [Abstract][Full Text] [Related]
6. [Chronic hepatitis C virus infection: clinical picture and treatment possibilities].
Annicchiarico BE; Siciliano M; Gasbarrini A
G Ital Nefrol; 2012; 29 Suppl 54():S103-8. PubMed ID: 22388839
[TBL] [Abstract][Full Text] [Related]
7. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
[TBL] [Abstract][Full Text] [Related]
8. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin.
Foster GR; Fried MW; Hadziyannis SJ; Messinger D; Freivogel K; Weiland O
Scand J Gastroenterol; 2007 Feb; 42(2):247-55. PubMed ID: 17327945
[TBL] [Abstract][Full Text] [Related]
9. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
[TBL] [Abstract][Full Text] [Related]
10. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
11. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
Perrella A; Sbreglia C; Atripaldi L; Esposito C; D'Antonio A; Perrella O
Scand J Gastroenterol; 2010; 45(2):250-5. PubMed ID: 19968615
[TBL] [Abstract][Full Text] [Related]
12. Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study.
Poo JL; Sánchez-Avila F; Kershenobich D; García-Samper X; Gongora J; Uribe M
J Gastroenterol Hepatol; 2004 Dec; 19 Suppl 6():S79-81. PubMed ID: 15546256
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice.
Gheorghe L; Grigorescu M; Iacob S; Damian D; Gheorghe C; Iacob R; Simionov I; Vadan R; Parvulescu I; Bancila I
Rom J Gastroenterol; 2005 Jun; 14(2):109-15. PubMed ID: 15990928
[TBL] [Abstract][Full Text] [Related]
14. Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C.
Baker RD; Dee D; Baker SS
J Clin Gastroenterol; 2007 Jan; 41(1):111-4. PubMed ID: 17198073
[TBL] [Abstract][Full Text] [Related]
15. Therapy of hepatitis C: from empiricism to eradication.
Pawlotsky JM
Hepatology; 2006 Feb; 43(2 Suppl 1):S207-20. PubMed ID: 16447262
[TBL] [Abstract][Full Text] [Related]
16. Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response.
Huang CF; Yang JF; Huang JF; Dai CY; Chiu CF; Hou NJ; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
J Gastroenterol Hepatol; 2010 Apr; 25(4):758-65. PubMed ID: 20492331
[TBL] [Abstract][Full Text] [Related]
17. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
Pár A; Tornai I; Szalay F
Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in patients with chronic hepatitis C, using viral and host factors: some concerns.
Dai CY; Chuang WL; Huang JF; Hsieh MY; Yu ML
Hepatology; 2009 Jun; 49(6):2125; author reply 2125-6. PubMed ID: 19479790
[No Abstract] [Full Text] [Related]
19. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus.
Pawlotsky JM
Hepatology; 2011 May; 53(5):1742-51. PubMed ID: 21374691
[TBL] [Abstract][Full Text] [Related]
20. Response-guided therapy: optimizing treatment now and in the future.
Marcellin P; Rizzetto M
Antivir Ther; 2008; 13 Suppl 1():1-2. PubMed ID: 18432156
[No Abstract] [Full Text] [Related]
[Next] [New Search]
